Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-CIDEB in adults with fibrotic MASH
2026-525916-33-00Phase 2Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing ALN-CIDEB with Placebo matching ALN-CIDEB (2 arms). Primary endpoint: Percent change from baseline in liver fat by MRI-PDFF. Planned start Oct 2026; status: authorised.
02
Drugs
ALN-CIDEB
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2026-525916-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525916-33-00.